Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials.
- DOI
- 10.1093/eurheartj/ehu085
- Published
- 2014 Sep 1
- Container
- European heart journal
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1093/eurheartj/ehu085,
title = {Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials.},
author = {Stein EA and Giugliano RP and Koren MJ and Raal FJ and Roth EM and Weiss R and Sullivan D and Wasserman SM and Somaratne R and Kim JB and Yang J and Liu T and Albizem M and Scott R and Sabatine MS and PROFICIO Investigators},
year = {2014},
journal = {European heart journal},
doi = {10.1093/eurheartj/ehu085},
url = {https://doi.org/10.1093/eurheartj/ehu085}
}RIS
TY - JOUR TI - Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials. AU - Stein EA AU - Giugliano RP AU - Koren MJ AU - Raal FJ AU - Roth EM AU - Weiss R AU - Sullivan D AU - Wasserman SM AU - Somaratne R AU - Kim JB AU - Yang J AU - Liu T AU - Albizem M AU - Scott R AU - Sabatine MS AU - PROFICIO Investigators PY - 2014 JO - European heart journal DO - 10.1093/eurheartj/ehu085 UR - https://doi.org/10.1093/eurheartj/ehu085 ER -
APA
EA, S., RP, G., MJ, K., FJ, R., EM, R., R, W., D, S., SM, W., R, S., JB, K., J, Y., T, L., M, A., R, S., MS, S., & Investigators, P. (2014). Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials.. European heart journal. https://doi.org/10.1093/eurheartj/ehu085
Source records
- pubmed · retrieved 2026-09-25T14:27:14.099Z